THYROID DISEASES IN LYMPHOMA SURVIVORS
(Abstract release date: 05/19/16)
EHA Library. Simula M. 06/09/16; 132689; E1140
Dr. Maria Pina Simula
Contributions
Contributions
Abstract
Abstract: E1140
Type: Eposter Presentation
Background
Improvements in the treatment of both Hodgkin’s (HL) and non Hodgkin’s Lymphomas (nHL) have resulted in an increasing number of long term survivors. However this patient’s population is at high risk of developing late therapy related complications that can negatively affect their survival and quality of life. In this report we focus on thyroid diseases.
Aims
In our institution the HL and aggressive nHL long term survivors are followed up in a dedicated clinic since September 2014. Here we report preliminary data on thyropathies.
Methods
We have reviewed our lymphoma survivors database
Results
We have analyzed data regarding 469 consecutive patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 were affected by HL and 222 by nHL. Two hundred thirty three were females, 236 males; median age at diagnosis was 29 years for HL (range 13-84), 48 years for nHL (range 12-83); median age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88).The median duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37).One hundred eight patients (23%) experienced thyroid disorders; they were 85 females (79%) and 23 males (11%), 77 have been treated for HL (71%) and 31(29%) for nHL.Thyroid diseases observed in our patients were: hypothyroidisms in 54, autoimmune thyroiditis in 24, nodules in 10, goiters in 10,carcinomas in 8, hyperthyroidism in 2 (table1). Thirteen of these patients had thyroid exeresis after thyroid disease diagnosis (table2).Regarding the previous therapies in thyroid disease patients: mediastinal and/or neck radiotherapy has been administered to 83 (77%) of patients and chemotherapy in 99 (92%).The median time between diagnosis of lymphoma and diagnosis of thyroid problems was 10 years (range 0-33).Thirty four of these disorders (31%), including one carcinoma, have been detected during planned controls (hormonal dosage and echotomography ) in absence of symptoms.
Conclusion
In our Department we described a high number of cases of thyroid disorders in the lymphoma survivors population. These were more common in females, as in general population, and in previous HL, probably because of higher rate of radiotherapy received in the treatment of HL compared to nHL. Almost a third of these disorders were found by tests done for early diagnosis of late complications in asymptomatic patients. These results outline the importance of screening of thyropaties in this setting of this special population .
Session topic: E-poster
Type: Eposter Presentation
Background
Improvements in the treatment of both Hodgkin’s (HL) and non Hodgkin’s Lymphomas (nHL) have resulted in an increasing number of long term survivors. However this patient’s population is at high risk of developing late therapy related complications that can negatively affect their survival and quality of life. In this report we focus on thyroid diseases.
Aims
In our institution the HL and aggressive nHL long term survivors are followed up in a dedicated clinic since September 2014. Here we report preliminary data on thyropathies.
Methods
We have reviewed our lymphoma survivors database
Results
We have analyzed data regarding 469 consecutive patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 were affected by HL and 222 by nHL. Two hundred thirty three were females, 236 males; median age at diagnosis was 29 years for HL (range 13-84), 48 years for nHL (range 12-83); median age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88).The median duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37).One hundred eight patients (23%) experienced thyroid disorders; they were 85 females (79%) and 23 males (11%), 77 have been treated for HL (71%) and 31(29%) for nHL.Thyroid diseases observed in our patients were: hypothyroidisms in 54, autoimmune thyroiditis in 24, nodules in 10, goiters in 10,carcinomas in 8, hyperthyroidism in 2 (table1). Thirteen of these patients had thyroid exeresis after thyroid disease diagnosis (table2).Regarding the previous therapies in thyroid disease patients: mediastinal and/or neck radiotherapy has been administered to 83 (77%) of patients and chemotherapy in 99 (92%).The median time between diagnosis of lymphoma and diagnosis of thyroid problems was 10 years (range 0-33).Thirty four of these disorders (31%), including one carcinoma, have been detected during planned controls (hormonal dosage and echotomography ) in absence of symptoms.
Conclusion
In our Department we described a high number of cases of thyroid disorders in the lymphoma survivors population. These were more common in females, as in general population, and in previous HL, probably because of higher rate of radiotherapy received in the treatment of HL compared to nHL. Almost a third of these disorders were found by tests done for early diagnosis of late complications in asymptomatic patients. These results outline the importance of screening of thyropaties in this setting of this special population .
Session topic: E-poster
Abstract: E1140
Type: Eposter Presentation
Background
Improvements in the treatment of both Hodgkin’s (HL) and non Hodgkin’s Lymphomas (nHL) have resulted in an increasing number of long term survivors. However this patient’s population is at high risk of developing late therapy related complications that can negatively affect their survival and quality of life. In this report we focus on thyroid diseases.
Aims
In our institution the HL and aggressive nHL long term survivors are followed up in a dedicated clinic since September 2014. Here we report preliminary data on thyropathies.
Methods
We have reviewed our lymphoma survivors database
Results
We have analyzed data regarding 469 consecutive patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 were affected by HL and 222 by nHL. Two hundred thirty three were females, 236 males; median age at diagnosis was 29 years for HL (range 13-84), 48 years for nHL (range 12-83); median age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88).The median duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37).One hundred eight patients (23%) experienced thyroid disorders; they were 85 females (79%) and 23 males (11%), 77 have been treated for HL (71%) and 31(29%) for nHL.Thyroid diseases observed in our patients were: hypothyroidisms in 54, autoimmune thyroiditis in 24, nodules in 10, goiters in 10,carcinomas in 8, hyperthyroidism in 2 (table1). Thirteen of these patients had thyroid exeresis after thyroid disease diagnosis (table2).Regarding the previous therapies in thyroid disease patients: mediastinal and/or neck radiotherapy has been administered to 83 (77%) of patients and chemotherapy in 99 (92%).The median time between diagnosis of lymphoma and diagnosis of thyroid problems was 10 years (range 0-33).Thirty four of these disorders (31%), including one carcinoma, have been detected during planned controls (hormonal dosage and echotomography ) in absence of symptoms.
Conclusion
In our Department we described a high number of cases of thyroid disorders in the lymphoma survivors population. These were more common in females, as in general population, and in previous HL, probably because of higher rate of radiotherapy received in the treatment of HL compared to nHL. Almost a third of these disorders were found by tests done for early diagnosis of late complications in asymptomatic patients. These results outline the importance of screening of thyropaties in this setting of this special population .
Session topic: E-poster
Type: Eposter Presentation
Background
Improvements in the treatment of both Hodgkin’s (HL) and non Hodgkin’s Lymphomas (nHL) have resulted in an increasing number of long term survivors. However this patient’s population is at high risk of developing late therapy related complications that can negatively affect their survival and quality of life. In this report we focus on thyroid diseases.
Aims
In our institution the HL and aggressive nHL long term survivors are followed up in a dedicated clinic since September 2014. Here we report preliminary data on thyropathies.
Methods
We have reviewed our lymphoma survivors database
Results
We have analyzed data regarding 469 consecutive patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 were affected by HL and 222 by nHL. Two hundred thirty three were females, 236 males; median age at diagnosis was 29 years for HL (range 13-84), 48 years for nHL (range 12-83); median age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88).The median duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37).One hundred eight patients (23%) experienced thyroid disorders; they were 85 females (79%) and 23 males (11%), 77 have been treated for HL (71%) and 31(29%) for nHL.Thyroid diseases observed in our patients were: hypothyroidisms in 54, autoimmune thyroiditis in 24, nodules in 10, goiters in 10,carcinomas in 8, hyperthyroidism in 2 (table1). Thirteen of these patients had thyroid exeresis after thyroid disease diagnosis (table2).Regarding the previous therapies in thyroid disease patients: mediastinal and/or neck radiotherapy has been administered to 83 (77%) of patients and chemotherapy in 99 (92%).The median time between diagnosis of lymphoma and diagnosis of thyroid problems was 10 years (range 0-33).Thirty four of these disorders (31%), including one carcinoma, have been detected during planned controls (hormonal dosage and echotomography ) in absence of symptoms.
Conclusion
In our Department we described a high number of cases of thyroid disorders in the lymphoma survivors population. These were more common in females, as in general population, and in previous HL, probably because of higher rate of radiotherapy received in the treatment of HL compared to nHL. Almost a third of these disorders were found by tests done for early diagnosis of late complications in asymptomatic patients. These results outline the importance of screening of thyropaties in this setting of this special population .
Session topic: E-poster
{{ help_message }}
{{filter}}